Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$157.12
-0.2%
$140.70
$91.86
$254.15
$7.72B1.491.03 million shs247,085 shs
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$52.82
-1.9%
$53.73
$39.97
$72.83
$10.07B0.952.58 million shs1.67 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$45.91
+3.6%
$41.88
$21.86
$49.62
$12.59B0.282.49 million shs6.04 million shs
Icon Plc stock logo
ICLR
Icon
$150.06
-0.5%
$139.88
$125.10
$347.72
$12.12B1.171.10 million shs486,301 shs
PPD, Inc. stock logo
PPD
PPD
$47.28
$47.27
$31.54
$47.41
$16.61B1.961.91 million shsN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%+4.81%+9.63%+14.73%-21.99%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%-1.56%-4.27%+24.12%+22.29%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+5.13%+8.74%+32.80%+109.06%
Icon Plc stock logo
ICLR
Icon
0.00%+3.80%+7.48%-2.38%-52.81%
PPD, Inc. stock logo
PPD
PPD
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.047 of 5 stars
2.12.00.04.72.22.51.9
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
4.9422 of 5 stars
4.55.00.04.73.42.50.6
Exelixis, Inc. stock logo
EXEL
Exelixis
4.7442 of 5 stars
2.31.00.04.33.42.54.4
Icon Plc stock logo
ICLR
Icon
4.372 of 5 stars
4.33.00.00.01.83.32.5
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.19
Hold$171.859.37% Upside
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
2.95
Moderate Buy$70.4033.30% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.52
Moderate Buy$43.56-5.13% Downside
Icon Plc stock logo
ICLR
Icon
2.60
Moderate Buy$213.0842.00% Upside
PPD, Inc. stock logo
PPD
PPD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ICLR, PPD, CRL, EXAS, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$47.00 ➝ $53.00
6/24/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$50.00
6/24/2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.00
6/24/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$29.00 ➝ $60.00
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00 ➝ $55.00
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$47.00 ➝ $50.00
6/12/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $47.00
6/5/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$45.00 ➝ $46.00
5/23/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/15/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$45.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.91$21.70 per share7.24$67.80 per share2.32
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$2.76B3.61$5.57 per share9.48$12.98 per share4.07
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.17B5.77$1.92 per share23.96$7.86 per share5.84
Icon Plc stock logo
ICLR
Icon
$8.28B1.46$20.03 per share7.49$117.92 per share1.27
PPD, Inc. stock logo
PPD
PPD
$4.68B3.55$1.99 per share23.71($1.21) per share-39.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A14.285.32-0.66%15.19%6.93%8/6/2025 (Estimated)
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$1.03B-$5.51N/A105.6311.39-36.06%-3.75%-1.68%7/30/2025 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$521.27M$2.2020.8718.000.9327.99%28.81%21.94%8/5/2025 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$9.1816.359.811.849.25%11.46%6.49%7/23/2025 (Estimated)
PPD, Inc. stock logo
PPD
PPD
$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/A

Latest ICLR, PPD, CRL, EXAS, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.04N/AN/AN/A$774.43 millionN/A
7/23/2025Q2 2025
Icon Plc stock logo
ICLR
Icon
$3.18N/AN/AN/A$1.98 billionN/A
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
5/1/2025Q1 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million
4/30/2025Q1 2025
Icon Plc stock logo
ICLR
Icon
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.73
2.38
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.50
3.44
Icon Plc stock logo
ICLR
Icon
0.36
1.27
1.27
PPD, Inc. stock logo
PPD
PPD
N/A
1.23
1.23

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Icon Plc stock logo
ICLR
Icon
95.61%
PPD, Inc. stock logo
PPD
PPD
87.82%

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.82%
Icon Plc stock logo
ICLR
Icon
44.00%
PPD, Inc. stock logo
PPD
PPD
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,000188.64 million186.37 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,147272.71 million265.02 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
PPD, Inc. stock logo
PPD
PPD
26,000351.40 million344.72 millionNot Optionable

Recent News About These Companies

69-year-old man missing in Portsmouth: PPD
PPD, CSPD: How to report illegal fireworks
Crash shuts down TN highway

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$157.12 -0.37 (-0.23%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$157.12 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

$52.82 -1.05 (-1.94%)
Closing price 07/3/2025 03:12 PM Eastern
Extended Trading
$52.82 0.00 (0.00%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$45.91 +1.61 (+3.63%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$45.95 +0.04 (+0.09%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Icon stock logo

Icon NASDAQ:ICLR

$150.06 -0.77 (-0.51%)
Closing price 07/3/2025 01:48 PM Eastern
Extended Trading
$150.06 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

PPD stock logo

PPD NASDAQ:PPD

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.